Sociedad Americana de Hirudoterapia

Early venous congestion after diep flap breast reconstruction: case report of a successful management

Case report published in Acta Biomed (2022)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportEnsayos clínicosBaccarani A et al. · Acta bio-medica : Atenei Parmensis, 2022

Abstract

More than 250 000 women estimated to be diagnosed with breast cancer in the USA every year. Mastectomy is primary treatment for more than a third of those with early-stage disease. Most of the patients undergoing mastectomy receive breast reconstruction. A number of. Surgical techniques have been described to reconstruct the breast. With autologous tissue breast reconstruction, the plastic surgeon uses patient's own tissues, taken from a different part of the body where there is an excess of fat and skin. Deep inferior epigastric perforator (DIEP) flap is the autologous breast reconstruction technique of choice in our department due to long lasting results, low donor site morbidity and positive patient reported outcomes have been described.   Case Report: We present the case of a 42-year-old woman who underwent neoadjuvant chemotherapy followed by left breast simple mastectomy, axillary lymph-nodes dissection and later adjuvant radiation therapy (RT). After conclusion of RT a DIEP flap breast reconstruction was performed. Nine-hours after the operation, signs of acute venous congestion were noted. The venous congestion was treated by a combined surgical and medical approach based on pedicle discharge and ICU resuscitation protocol. After take back surgery, the patient was tightly monitored in the intensive care unit where intravenous heparin infusion and leech therapy were performed for 2 days. Flap congestion resolved completely, and the patient was discharged.   Conclusions: Venous congestion is very difficult to treat due to its potential multifactorial nature. The most important step is to recognize this kind of emergency because irreversible microvascular damages will develop in 6-8 hours. Because of multiple causes of venous congestion a timely multidisciplinary approach is mandatory, to maximize flap salvage and success rates.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article
Indexed MeSH termsAdultBreast NeoplasmsFemaleHumansHyperemiaMammaplastyMastectomyPerforator Flap

Resumen

42-year-old woman with DIEP flap breast reconstruction post-RT developed acute venous congestion 9 hours postop; managed with surgical pedicle discharge, heparin infusion and 2 days of leech therapy with complete flap survival.

Por qué esto importa para la hirudoterapia

Este informe de caso describe a una mujer de 42 años que desarrolló congestión venosa aguda nueve horas después de una reconstrucción mamaria con colgajo DIEP y fue tratada con un enfoque quirúrgico y médico combinado, que incluyó infusión intravenosa de heparin y terapia con sanguijuelas durante dos días en la UCI, después de lo cual la congestión del colgajo se resolvió por completo y fue dada de alta. Es directamente relevante para la hirudoterapia como un caso clínico documentado de sanguijuelas medicinales utilizadas como parte de la descongestión para el rescate del colgajo, y subraya el punto de los autores de que la congestión venosa debe reconocerse y tratarse dentro del margen de 6-8 horas antes de que ocurra un daño microvascular irreversible. Como informe de caso de un solo paciente que combina varias intervenciones, no puede aislar la contribución de las sanguijuelas ni establecer su eficacia; es un apoyo anecdótico para el papel de rescate establecido de la terapia con sanguijuelas, no una evidencia comparativa.

Citación

Early venous congestion after diep flap breast reconstruction: case report of a successful management.

Baccarani A et al. · Acta bio-medica : Atenei Parmensis, 2022

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.